PAX4 gene delivery improves β-cell function in human islets of Type II diabetes.
Yanqing ZhangKeshab R ParajuliVivian A FonsecaHongju WuPublished in: Regenerative medicine (2024)
Aim: Type II diabetes (T2D) stems from insulin resistance, with β-cell dysfunction as a hallmark in its progression. Studies reveal that β cells undergo apoptosis or dedifferentiation during T2D development. The transcription factor PAX4 is vital for β differentiation and survival, thus may be a potential enhancer of β-cell function in T2D islets. Materials & methods: Human PAX4 cDNA was delivered into T2D human islets with an adenoviral vector, and its effects on β cells were examined. Results: PAX4 gene delivery significantly improved β-cell survival, and increased β-cell composition in the T2D human islets. Basal insulin and glucose-stimulated insulin secretion in PAX4-expressing islets were substantially higher than untreated or control-treated T2D human islets. Conclusion: Introduced PAX4 expression in T2D human islets improves β-cell function, thus could provide therapeutic benefits for T2D treatment.
Keyphrases
- endothelial cells
- type diabetes
- transcription factor
- induced pluripotent stem cells
- insulin resistance
- pluripotent stem cells
- cardiovascular disease
- cell cycle arrest
- single cell
- metabolic syndrome
- gene expression
- adipose tissue
- cell death
- poor prognosis
- risk assessment
- cell therapy
- cell proliferation
- long non coding rna
- climate change
- signaling pathway
- high fat diet
- blood glucose
- weight loss
- replacement therapy